About Patheon NV
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PTHN
- Previous Close: $32.44
- 50 Day Moving Average: $29.39
- 200 Day Moving Average: $28.22
- 52-Week Range: $24.11 - $32.95
- Trailing P/E Ratio: 127.22
- Foreward P/E Ratio: 19.43
- P/E Growth: 1.14
- Market Cap: $4.71B
- Outstanding Shares: 145,074,000
What is Patheon NV's stock symbol?
Patheon NV trades on the NASDAQ under the ticker symbol "PTHN."
Where is Patheon NV's stock going? Where will Patheon NV's stock price be in 2017?
12 equities research analysts have issued 1-year price objectives for Patheon NV's shares. Their forecasts range from $30.00 to $33.00. On average, they anticipate Patheon NV's stock price to reach $31.80 in the next twelve months.
When will Patheon NV announce their earnings?
Patheon NV is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Patheon NV stock?
Here are some recent quotes from research analysts about Patheon NV stock:
According to Zacks Investment Research, "Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands. " (12/22/2016)
Jefferies Group LLC analysts commented, "New top-line data suggests GLPG’s potentiator ‘1837 is likely active; still, comparisons to Kalydeco are difficult, and multiple GLPG correctors/ potentiators would still need to work both individually and in concert for their portfolio to represent a meaningful threat to VRTX." (12/21/2016)
Morgan Stanley analysts commented, "High operating leverage can drive ~330 bps in EBITDA margin expansion by FY18; we see EPS growth of 58 percent/20 percent in FY17/FY18," analyst Ricky Goldwasser wrote in a note.Goldwasser said the company is poised to expand its CMO share due to its open platform, end-to-end service, quality and global footprint.Related Link: Wells Fargo Initiates Coverage On Patheon At OutperformForward ViewAs such, the analyst believes Patheon can grow its top line at an 11 percent/8 percent CAGR in FY17/FY18, above market growth rates of 5–6 percent, with 209 bps and 121 bps in EBITDA margin expansion in FY17/FY18. The analyst estimates Patheon can grow EBITDA margins from 21.6 percent in FY16 to 24.8 percent in FY18."Patheon is poised to thrive on biologics, the fastest growing area in drug development, given capabilities that span formulation / development as well as API," (8/15/2016)
Who owns Patheon NV stock?
Patheon NV's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (1.40%), Alyeska Investment Group L.P. (0.63%), Franklin Resources Inc. (0.52%), Janus Capital Management LLC (0.33%), Meru Capital Group LP (0.32%) and State Street Corp (0.27%). Company insiders that own Patheon NV stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman.
Who sold Patheon NV stock? Who is selling Patheon NV stock?
Patheon NV's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Highland Capital Management LP, Fred Alger Management Inc., BlueMar Capital Management LLC, TCW Group Inc. and Alyeska Investment Group L.P..
Who bought Patheon NV stock? Who is buying Patheon NV stock?
Patheon NV's stock was acquired by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Meru Capital Group LP, State Street Corp, Franklin Resources Inc., Friess Associates LLC, GSA Capital Partners LLP, Guggenheim Capital LLC and State Board of Administration of Florida Retirement System. Company insiders that have bought Patheon NV stock in the last two years include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman.
How do I buy Patheon NV stock?
Shares of Patheon NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Patheon NV stock cost?
One share of Patheon NV stock can currently be purchased for approximately $32.44.